vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and GLOBAL INDUSTRIAL Co (GIC). Click either name above to swap in a different company.
GLOBAL INDUSTRIAL Co is the larger business by last-quarter revenue ($345.6M vs $196.0M, roughly 1.8× Axsome Therapeutics, Inc.). GLOBAL INDUSTRIAL Co runs the higher net margin — 4.2% vs -14.6%, a 18.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 14.3%). GLOBAL INDUSTRIAL Co produced more free cash flow last quarter ($19.2M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 3.4%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Global Industrial Company is a Port Washington, New York–based company providing industrial and MRO products through a system of branded e-Commerce websites and relationship marketers in North America. The primary brand is Global Industrial.
AXSM vs GIC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $345.6M |
| Net Profit | $-28.6M | $14.6M |
| Gross Margin | — | 34.5% |
| Operating Margin | -13.8% | 5.7% |
| Net Margin | -14.6% | 4.2% |
| Revenue YoY | 65.0% | 14.3% |
| Net Profit YoY | 61.9% | 36.4% |
| EPS (diluted) | $-0.55 | $0.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $345.6M | ||
| Q3 25 | $171.0M | $353.6M | ||
| Q2 25 | $150.0M | $358.9M | ||
| Q1 25 | $121.5M | $321.0M | ||
| Q4 24 | $118.8M | $302.3M | ||
| Q3 24 | $104.8M | $342.4M | ||
| Q2 24 | $87.2M | $347.8M | ||
| Q1 24 | $75.0M | $323.4M |
| Q4 25 | $-28.6M | $14.6M | ||
| Q3 25 | $-47.2M | $18.8M | ||
| Q2 25 | $-48.0M | $25.1M | ||
| Q1 25 | $-59.4M | $13.6M | ||
| Q4 24 | $-74.9M | $10.7M | ||
| Q3 24 | $-64.6M | $16.8M | ||
| Q2 24 | $-79.3M | $20.3M | ||
| Q1 24 | $-68.4M | $13.2M |
| Q4 25 | — | 34.5% | ||
| Q3 25 | — | 35.6% | ||
| Q2 25 | — | 37.1% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 33.8% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 35.2% | ||
| Q1 24 | — | 34.3% |
| Q4 25 | -13.8% | 5.7% | ||
| Q3 25 | -27.0% | 7.4% | ||
| Q2 25 | -24.5% | 9.3% | ||
| Q1 25 | -46.9% | 5.7% | ||
| Q4 24 | -61.1% | 4.8% | ||
| Q3 24 | -59.8% | 6.5% | ||
| Q2 24 | -89.5% | 7.6% | ||
| Q1 24 | -89.7% | 5.4% |
| Q4 25 | -14.6% | 4.2% | ||
| Q3 25 | -27.6% | 5.3% | ||
| Q2 25 | -32.0% | 7.0% | ||
| Q1 25 | -48.9% | 4.2% | ||
| Q4 24 | -63.1% | 3.5% | ||
| Q3 24 | -61.7% | 4.9% | ||
| Q2 24 | -91.0% | 5.8% | ||
| Q1 24 | -91.1% | 4.1% |
| Q4 25 | $-0.55 | $0.37 | ||
| Q3 25 | $-0.94 | $0.48 | ||
| Q2 25 | $-0.97 | $0.65 | ||
| Q1 25 | $-1.22 | $0.35 | ||
| Q4 24 | $-1.54 | $0.28 | ||
| Q3 24 | $-1.34 | $0.44 | ||
| Q2 24 | $-1.67 | $0.52 | ||
| Q1 24 | $-1.44 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $67.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $313.2M |
| Total Assets | $689.8M | $580.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $67.5M | ||
| Q3 25 | $325.3M | $67.2M | ||
| Q2 25 | $303.0M | $55.1M | ||
| Q1 25 | $300.9M | $39.0M | ||
| Q4 24 | $315.4M | $44.6M | ||
| Q3 24 | $327.3M | $38.9M | ||
| Q2 24 | $315.7M | $38.8M | ||
| Q1 24 | $331.4M | $29.9M |
| Q4 25 | $88.3M | $313.2M | ||
| Q3 25 | $73.7M | $316.0M | ||
| Q2 25 | $73.1M | $305.2M | ||
| Q1 25 | $53.2M | $287.9M | ||
| Q4 24 | $57.0M | $281.1M | ||
| Q3 24 | $92.9M | $279.2M | ||
| Q2 24 | $102.9M | $270.4M | ||
| Q1 24 | $144.0M | $260.2M |
| Q4 25 | $689.8M | $580.8M | ||
| Q3 25 | $669.3M | $602.5M | ||
| Q2 25 | $639.8M | $586.5M | ||
| Q1 25 | $596.7M | $536.7M | ||
| Q4 24 | $568.5M | $520.7M | ||
| Q3 24 | $561.5M | $531.6M | ||
| Q2 24 | $548.2M | $542.5M | ||
| Q1 24 | $545.7M | $517.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $20.0M |
| Free Cash FlowOCF − Capex | $-18.7M | $19.2M |
| FCF MarginFCF / Revenue | -9.6% | 5.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 1.37× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $74.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $20.0M | ||
| Q3 25 | $1.0M | $22.7M | ||
| Q2 25 | $-32.4M | $31.7M | ||
| Q1 25 | $-43.4M | $3.4M | ||
| Q4 24 | $-26.2M | $15.9M | ||
| Q3 24 | $-18.6M | $9.6M | ||
| Q2 24 | $-30.1M | $18.8M | ||
| Q1 24 | $-53.5M | $6.4M |
| Q4 25 | $-18.7M | $19.2M | ||
| Q3 25 | $988.0K | $22.0M | ||
| Q2 25 | $-32.4M | $30.3M | ||
| Q1 25 | $-43.7M | $3.2M | ||
| Q4 24 | $-26.2M | $15.2M | ||
| Q3 24 | $-18.7M | $8.7M | ||
| Q2 24 | $-30.2M | $17.9M | ||
| Q1 24 | $-53.6M | $5.1M |
| Q4 25 | -9.6% | 5.6% | ||
| Q3 25 | 0.6% | 6.2% | ||
| Q2 25 | -21.6% | 8.4% | ||
| Q1 25 | -36.0% | 1.0% | ||
| Q4 24 | -22.1% | 5.0% | ||
| Q3 24 | -17.9% | 2.5% | ||
| Q2 24 | -34.6% | 5.1% | ||
| Q1 24 | -71.4% | 1.6% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.0% | 0.2% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 0.0% | 0.2% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.1% | 0.3% | ||
| Q1 24 | 0.1% | 0.4% |
| Q4 25 | — | 1.37× | ||
| Q3 25 | — | 1.21× | ||
| Q2 25 | — | 1.26× | ||
| Q1 25 | — | 0.25× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 0.57× | ||
| Q2 24 | — | 0.93× | ||
| Q1 24 | — | 0.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
